Products
Tofogliflozin was approved in Japan in 2014 (initial registration, Apleway, Deberza). The drug is not currently registered in many countries.
Structure and properties
Tofogliflozin (C22H26O6, Mr = 386.4 g/mol)
Effects
Tofogliflozin has antidiabetic and antihyperglycemic properties. It is a selective inhibitor of sodium–glucose co-transporter 2 (SGLT2). This transporter is responsible for the reabsorption of glucose at the proximal tubule of the nephron. Inhibition leads to increased excretion of the sugar via the urine. The mechanism of action is independent of insulin, unlike other antidiabetic agents. Tofogliflozin is specific for SGLT2 and does not inhibit SGLT1, which is responsible for glucose absorption in the intestine.
Indications
For the treatment of type 2 diabetes.
Dosage
According to the SmPC. The medicine is taken once daily before or after breakfast.
